| This week's sponsor is SynteractHCR. | | | |
Featured Story | | | Friday, September 1, 2017 Janssen is ending a license deal with MacroGenics for duvortuxizumab, a CD19- and CD3-targeting drug for B-cell malignancies it paid $125 million upfront for in 2014, but isn’t severing ties with the biotech entirely. |
|
|
Top Stories Friday, September 1, 2017 Nightstar Therapeutics has filed to raise up to $86 million in a Nasdaq IPO. The money will equip Nightstar to complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage clinical studies. Friday, September 1, 2017 Akcea Therapeutics has filed for FDA approval of volanesorsen. The Ionis Pharmaceuticals spinout sees the filing positioning it to bring the treatment of familial chylomicronemia syndrome to market in the U.S. next year. Friday, September 1, 2017 BrainScope has raised $16 million to commercialize its device for triaging patients with potential traumatic brain injury. The financing round comes one year after the FDA granted 510(k) clearance to the latest iteration of the device. Thursday, August 31, 2017 HIV treatments have made enormous strides in recent decades, but patients—even those on antiretroviral drugs—have a higher risk of developing heart disease. An experimental drug based on tick saliva may be the key to reducing the inflammation that causes these complications. Thursday, August 31, 2017 In this week's EuroBiotech Report, Novartis bags Xoma drug, AstraZeneca teams with Takeda, U.K. sets out a life science vision and more. Friday, September 1, 2017 Takeda is paying AstraZeneca up to $400 million to co-develop a Parkinson’s candidate, Samsung Bioepis gained an EU approval for its Humira copycat Imraldi, Daiichi Sankyo said a Nikkei story about it spurning an AstraZeneca bid did not reflect the fact and more. Thursday, August 31, 2017 Sanofi's diabetes and cardiovascular chief Peter Guenter is leaving for the CEO post at Almirall, FDA CDER's deputy director Richard Moscicki will join PhRMA as CMO and EVP, Biogen biosimilar unit head Alpna Seth joined her former boss George Scangos at Vir Biotechnology, plus more hirings, firings and retirings throughout the industry. Resources Sponsored by: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. Presented By: PRA Health Sciences Children participating in pediatric clinical trials are included in the contraceptive requirements applied to women of child-bearing potential, creating significant challenges for sponsors, parents, investigators and study staff. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. 2nd Strategic Partnerships for Drug Repurposing October 26-27, 2017 | Boston, MA Now Accepting Applications: Fierce Innovation Awards Life Science Edition FierceBiotech 2nd Drug Development Forum September 25-27, 2017 | Boston, MA FierceBiotech Executive Summit- London October 2, 2017 | London 11th Digital Pharma East October 3-6, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 